Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.64 |
| ▸ | IKBKB | O14920 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.52 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.52 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.52 |
| ▸ | DKK1 | O94907 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17261032 | 0.87 | KDR (0.70) | KDRIKBKBCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4810259 | 0.87 | KDR (0.75) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13980537 | 0.84 | KDR (0.72) | KDRAURKA | |
| SCHEMBL18780744 | 0.82 | SCN9A (0.50) | KDRPARP1 | |
| SCHEMBL30629807 | 0.81 | KDR (0.51) | KDRIKBKBCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL26114981 | 0.81 | KDR (0.51) | KDRIKBKBCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4816190 | 0.81 | KDR (0.83) | KDRAURKARIPK1MLKLRIPK3 | |
| SCHEMBL13980540 | 0.80 | KDR (0.54) | KDRAURKA | |
| SCHEMBL17261079 | 0.80 | KDR (0.51) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17260968 | 0.79 | KDR (0.77) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114025-A1 | METHODS FOR INHIBITING NECROPTOSIS | CATALYST THERAPEUTICS PTY LTD (AU) | 2017-04-27 | — | — | US | disclosed |
| US-20170114025-A1 | METHODS FOR INHIBITING NECROPTOSIS | CATALYST THERAPEUTICS PTY LTD (AU) | 2017-04-27 | — | — | US | disclosed |
| EP-3142667-A1 | METHODS FOR INHIBITING NECROPTOSIS | Catalyst Therapeutics Pty Ltd. (AU) | 2017-03-22 | — | — | EP | disclosed |
| WO-2015172203-A1 | METHODS FOR INHIBITING NECROPTOSIS | CATALYST THERAPEUTICS PTY LTD (AU) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015172203-A1 | METHODS FOR INHIBITING NECROPTOSIS | CATALYST THERAPEUTICS PTY LTD (AU) | 2015-11-19 | — | — | WO | disclosed |
| US-7459455-B2 | Pyrimidine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459455-B2 | Pyrimidine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459455-B2 | Pyrimidine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050085637-A1 | Antiproliferative agents; angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114025-A1 | METHODS FOR INHIBITING NECROPTOSIS | RIPK1, RIPK3, RIPK2 | KDR 4376/4885IKBKB 227/4885CYP3A4 4866/4885 |
| US-20050085637-A1 | Antiproliferative agents; angiogenesis inhibitors | TIE1, TEK, KDR | KDR 3/4885IKBKB 554/4885CYP3A4 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.